{"id":"W4403303574","doi":"10.1111/pcmr.13205","title":"Meeting Report From the 2023 Cure Ocular Melanoma (<scp>CURE OM</scp>) Global Science Meeting, Philadelphia, <scp>PA</scp>, November 2023","year":2024,"lang":"en","type":"article","venue":"Pigment Cell & Melanoma Research","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Patient Safety Institute","funders":"EMD Serono; Genentech; Plexxikon; Astellas Pharma; Eisai; Castle Biosciences; G1 Therapeutics; Ascentage Pharma; Pfizer; Moderna; Incyte; BeiGene; Melanoma Research Foundation; GlaxoSmithKline; Tizona Therapeutics; AstraZeneca; Novocure; Mereo BioPharma; Celldex Therapeutics; Daiichi Sankyo Europe; Foghorn Therapeutics; Gilead Sciences; Regeneron Pharmaceuticals; Melanoma Research Alliance; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; NGM Biopharmaceuticals; Exelixis; Sanofi","keywords":"Medicine; Melanoma; Gerontology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001784743,0.0007749279,0.0003447564,0.0006373518,0.0009984985,0.001887789,0.0006255792,0.00269546,0.09139881],"category_scores_gemma":[0.002701072,0.000218327,0.0007112083,0.0003538371,0.0001648089,0.0006820835,0.0009613836,0.002514373,0.03743762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001167388,"about_ca_system_score_gemma":0.002639582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006930449,"about_ca_topic_score_gemma":0.01178578,"domain_scores_codex":[0.9991867,0.0001367313,0.00004000805,0.00007632631,0.000432211,0.0001279347],"domain_scores_gemma":[0.9977289,0.000201806,0.0000887256,0.00003917901,0.001387246,0.0005541245],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006487771,0.00002751579,0.0002003421,0.00006878196,0.000004507818,0.00008554406,0.0000127843,0.00002020846,0.0001649889,0.00009564194,0.9891483,0.01010647],"study_design_scores_gemma":[0.00003107155,0.00006135598,0.001239041,0.0001156968,0.00001047809,0.0001126984,0.000106283,0.00005484688,0.0002119851,0.0001223362,0.9979254,0.000008940588],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.006357612,0.03044382,0.002566646,0.2467687,0.3418645,0.001586845,0.01784892,0.0004355255,0.3521275],"genre_scores_gemma":[0.02433176,0.02290695,0.002718123,0.06993978,0.05857953,0.00122398,0.01140933,0.0003393437,0.8085512],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.09139881,"threshold_uncertainty_score":0.3057595,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04097590354583888,"score_gpt":0.358749423360031,"score_spread":0.3177735198141921,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}